Accurate diagnosis and treatment of neuropsychiatric diseases, such as Alzheimer’s disease, schizophrenia, bipolar disorder, depression, stress, and anxiety, are often complicated by aetiological and clinical heterogeneity. There is a need for a greater range of diagnostic tools for early detection of such disorders. This can help with improved prediction of forthcoming disease, diagnostic precision, disease severity description, and improved treatment choice. The metabolic changes in various disease states can be captured using metabolomics, an approach that may often have pre-clinical biomarkers of neurological diseases. Proteomic technologies, which are based on mass spectrometry techniques, hold great promise in investigating disease-specific protein signatures of psychiatric disorders. It is hoped that proteomics and metabolomics will allow researchers and clinicians to study neuropsychiatric disorders in new ways and enable new discoveries to be made. This chapter focuses on the role of proteomics and metabolomics in neuropsychiatry research.
Correction: Disease-specific protein corona sensor arrays may have disease detection capacity
